Current development in novel drug delivery systems of bioactive molecule plumbagin
Source abstract
Abstract
Plumbagin (PLB), a member of the quinine family, mainly found in the plant Plumbago zeylanica Linn., potentially exhibit anticancer, anti-inflammatory, anti-oxidant, antifungal, neuroprotective, hypolipidemic and antibacterial activities. However, it has been well known that the application of PLB was limited owing to its water insolubility, instability and poor bioavailability. For decades, many attempts have been made to compensate for these disadvantages with the development of improved delivery platforms as the feasible approaches. This review aims to describe the various studies supporting the biopharmaceutical aspects of PLB. In addition, it includes a section devoted to discussing the challenges associated with the drug and strategies to improve the properties of PLB such as solubility, stability and bioavailability. Also, this paper summarizes the recent works on the design and development of novel delivery systems of PLB such as liposomes, niosomes, microsphares, nanoparticles, micelles, complexization, metal nanoparticles, crystals modification, etc., with the goal of harnessing the true difficulties of this multifunctional agent in the clinical arena.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Bioactive Compounds and Antitumor Agents · Synthesis of Indole Derivatives · Nigella sativa pharmacological applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, Dr D. Y. Patil College of Pharmacy
Department of Pharmacology, Dr D. Y. Patil College of Pharmacy
Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University
Department of Pharmaceutics, Government College of Pharmacy
References (50)
Show source-provided references
1. Salanki A, Kutty SK. Plant derived compounds in clinical trials. Drug Discov Today. 2007;13:161–171.
2. 10.1016/j.fitote.2010.05.00110.1016/j.fitote.2010.05.001 ↗
3. 10.1016/j.exppara.2015.12.00110.1016/j.exppara.2015.12.001 ↗
4. 10.1021/np300040910.1021/np3000409 ↗
5. 10.1002/ptr.86710.1002/ptr.867 ↗
6. 10.1007/s00011-007-7163-610.1007/s00011-007-7163-6 ↗
7. 10.2119/molmed.2015.0025010.2119/molmed.2015.00250 ↗
8. 10.1007/BF0270307110.1007/BF02703071 ↗
9. 10.1016/S0166-6851(99)00180-210.1016/S0166-6851(99)00180-2 ↗
10. 10.1158/0008-5472.CAN-08-249410.1158/0008-5472.CAN-08-2494 ↗
11. 10.1159/00021002810.1159/000210028 ↗
12. 10.1158/1541-7786.MCR-09-025710.1158/1541-7786.MCR-09-0257 ↗
13. 10.7314/APJCP.2013.14.4.232510.7314/APJCP.2013.14.4.2325 ↗
14. 10.1124/jpet.105.09886310.1124/jpet.105.098863 ↗
15. 10.1007/s11010-009-0254-710.1007/s11010-009-0254-7 ↗
16. 10.1016/j.canlet.2007.10.00510.1016/j.canlet.2007.10.005 ↗
17. 10.1111/j.1872-034X.2009.00540.x10.1111/j.1872-034X.2009.00540.x ↗
18. 10.1211/002235705511910.1211/0022357055119 ↗
19. 10.1002/mc.2003110.1002/mc.20031 ↗
20. 10.1016/j.vph.2006.02.00110.1016/j.vph.2006.02.001 ↗
21. 10.1016/j.molstruc.2014.12.02510.1016/j.molstruc.2014.12.025 ↗
22. 10.1016/j.jchromb.2006.06.02410.1016/j.jchromb.2006.06.024 ↗
23. 10.1038/srep2848210.1038/srep28482 ↗
24. 10.1504/IJSURFSE.2013.05370810.1504/IJSURFSE.2013.053708 ↗
25. 10.1080/21691401.2017.129064710.1080/21691401.2017.1290647 ↗
26. 10.1080/21691401.2017.128249610.1080/21691401.2017.1282496 ↗
27. 10.1080/106118602100005492410.1080/1061186021000054924 ↗
28. 10.3109/10717544.2011.59584010.3109/10717544.2011.595840 ↗
29. 10.1016/S0031-6997(24)01426-110.1016/S0031-6997(24)01426-1 ↗
30. 10.1080/21691401.2017.129685010.1080/21691401.2017.1296850 ↗
31. D’Souza Singh UV, Aithal KS, et al. Antifertility activity of niosomal HPβCD-Plumbagin complex. Indian J Pharm Sci. 1998;60:36–40.
32. 10.1211/14608089912873485710.1211/146080899128734857 ↗
33. 10.1111/j.2042-7158.1996.tb03907.x10.1111/j.2042-7158.1996.tb03907.x ↗
34. Kini DP, Pandey S, Shenoy BD, et al. Antitumor and antifertility activities of plumbagin controlled release formulations. Indian J Exp Biol. 1997;35:374–379.
35. 10.1080/21691401.2017.137328410.1080/21691401.2017.1373284 ↗
36. 10.1080/21691401.2017.137667510.1080/21691401.2017.1376675 ↗
37. Indhumathi D, Remya PN, Sangeetha S. Formulation trails on nanoparticular preparation for easy scale up through different techniques. J Chem Pharm Sci. 2013;6:170–174.
38. 10.4155/tde.13.9210.4155/tde.13.92 ↗
39. 10.1039/C6RA12714B10.1039/C6RA12714B ↗
40. 10.1080/21691401.2016.119302410.1080/21691401.2016.1193024 ↗
41. Singh UV, Bisht KS, Rao S, et al. Plumbagin-loaded PLGA microspheres with and enhanced antitumour efficacy reduced in mice toxicity. Pharm Pharmacol Commun. 1996;2:407–409.
42. 10.3109/1071754090354844710.3109/10717540903548447 ↗
43. 10.3109/21691401.2016.116091510.3109/21691401.2016.1160915 ↗
44. 10.2147/IJN.S2407410.2147/IJN.S24074 ↗
45. 10.1049/iet-nbt.2015.000810.1049/iet-nbt.2015.0008 ↗
46. 10.1158/1538-7445.AM2016-220810.1158/1538-7445.AM2016-2208 ↗
47. 10.1155/2014/17914910.1155/2014/179149 ↗
48. 10.1039/C4MT00165F10.1039/C4MT00165F ↗
49. 10.1504/IJSURFSE.2013.05370810.1504/IJSURFSE.2013.053708 ↗
50. 10.1088/2053-1591/1/2/02540510.1088/2053-1591/1/2/025405 ↗